Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Observational 4Interventional 3

Sponsor

Cancer Type

Myeloid 3Thoracic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Myelodysplastic Syndromes 1349Leukemia, Myeloid, Acute 1133Leukemia, Myelogenous, Chronic, BCR-ABL Positive 713Leukemia 675Precursor Cell Lymphoblastic Leukemia-Lymphoma 646Myeloproliferative Disorders 527Leukemia, Myelomonocytic, Chronic 424Lymphoma, Non-Hodgkin 407Primary Myelofibrosis 384Multiple Myeloma 369Leukemia, Lymphocytic, Chronic, B-Cell 367Hodgkin Disease 348Leukemia, Myeloid, Chronic-Phase 304Lymphoma 291Blast Crisis 256Leukemia, Myeloid, Accelerated Phase 238Lymphoma, Mantle-Cell 231Lymphoma, Follicular 226Burkitt Lymphoma 224Polycythemia Vera 222Lymphoma, Large B-Cell, Diffuse 219Lymphoma, B-Cell, Marginal Zone 203Congenital Abnormalities 192Anemia, Refractory, with Excess of Blasts 187Lymphoma, Large-Cell, Immunoblastic 182Myelodysplastic-Myeloproliferative Diseases 175Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 173Thrombocythemia, Essential 167Neoplasms, Plasma Cell 161Hematologic Neoplasms 161

Interventions

ripretinib 1Imatinib Mesylate 1Cladribine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Mast Cell Activation Disorders × Myeloid × Clear all
NCT02571036 2023-12-13

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Deciphera Pharmaceuticals, LLC

Phase 1 Completed
282 enrolled
CNSDermatologicGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmSarcomaThoracic

Mast Cell Activation Disorders, Carcinoma, Non-Small-Cell Lung, Glioma, Leukemia, Mast-Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Penile Neoplasms, Sarcoma, Mastocytosis, Systemic, Gastrointestinal Stromal Tumors, Renal Insufficiency

NCT01297777 2016-08-29

Imatinib in KIT-negative Systemic Mastocytosis

Hospital Virgen de la Salud

Phase 4 Completed
10 enrolled
Myeloid

Mast Cell Activation Disorders, Mastocytosis, Mastocytosis, Systemic

NCT01602939 2016-08-29

Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis

Hospital Virgen de la Salud

Phase 2/3 Unknown
10 enrolled
Myeloid

Mast Cell Activation Disorders, Mastocytosis, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡